Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes
Public ClinicalTrials.gov record NCT00789191. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effect of Detemir and Sitagliptin on Blood Glucose Control in Subjects With Type 2 Diabetes Mellitus
Study identification
- NCT ID
- NCT00789191
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 222 participants
Conditions and interventions
Conditions
Interventions
- insulin detemir Drug
- metformin Drug
- sitagliptin Drug
- sulphonylurea Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2008
- Primary completion
- Jul 31, 2009
- Completion
- Jul 31, 2009
- Last update posted
- Mar 13, 2017
2008 – 2009
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Vestavia Hills | Alabama | 35209 | — |
| Novo Nordisk Investigational Site | Orange | California | 92869 | — |
| Novo Nordisk Investigational Site | Santa Monica | California | 90404 | — |
| Novo Nordisk Investigational Site | Dunwoody | Georgia | 30338 | — |
| Novo Nordisk Investigational Site | West Seneca | New York | 14224 | — |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45245 | — |
| Novo Nordisk Investigational Site | Dayton | Ohio | 45439 | — |
| Novo Nordisk Investigational Site | Norristown | Pennsylvania | 19401 | — |
| Novo Nordisk Investigational Site | Chattanooga | Tennessee | 37411 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00789191, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 13, 2017 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00789191 live on ClinicalTrials.gov.